Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B5EB
|
|||
| Former ID |
DIB011699
|
|||
| Drug Name |
Ponezumab
|
|||
| Synonyms |
Neurological disease and injury therapeutics, Pfizer; PF-04360365; PF-4360365; RI-1014; RI-1219; RI-409; RN-1219
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Company |
Rinat Neuroscience Corp
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01821118) Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy. U.S. National Institutes of Health. | |||
| REF 2 | Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol. 2012 Aug 24;421(4-5):525-36. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.